An observational study in Non-Small Cell Lung Cancer, sponsored by Bristol-Myers Squibb. Completed at 1 site in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-05-27.
Sponsored by Bristol-Myers Squibb · Observational
This study is to capture and describe the patient and disease characteristics and the outcomes of adult patients with previously-treated advanced NSCLC who have been treated with Nivolumab
6,641 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,665 are open to participants now.
This study's enrollment of 503 is above the median of 164 across 974 observational studies indexed under Carcinoma, Non-Small-Cell Lung.
Browse Carcinoma, Non-Small-Cell Lung studies →Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 118 are open to participants now.
Of its 435 completed or terminated interventional studies of FDA-regulated products, 227 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Previously-treated advanced NSCLC patients commencing treatment with nivolumab between May 2015 and August 2017 under the Australian Patient Access Program
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria could apply
Other: Non-Interventional
Non-Interventional
Time to treatment failure (TTF)
Time frame: Approximately 27 months
Best overall response (BOR)
Time frame: Approximately 27 months
Progression free survival rate (PFSR)
Time frame: Approximately 27 months
Overall survival rate (OSR)
Time frame: Approximately 27 months
Incidence of AE's
Time frame: Approximately 27 months
Incidence of SAE's
Time frame: Approximately 27 months
Reasons for ceasing treatment
Any of the following: progressive disease, toxicity, patient wishes/preference, doctor decision, death
Time frame: Approximately 27 months
Incidence of patients with brain metastases
Time frame: Approximately 27 months
Incidence of re-treatment
Time frame: Approximately 27 months
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Non-Small-Cell Lung →